PILA PHARMA’s Post

One of the first drugs to come into everyday use is aspirin. It is still one of the most researched drugs in the world, with an estimated 700 to 1,000 clinical trials conducted each year. Aspirin's use can be traced back to when the Sumerians and Egyptians used willow as medicine circa 3000 BC. "Aspirin" was given its name in 1899 by Bayer and has been researched heavily ever since. . . . #ClinicalResearch #ResearchTrials #ClinicalStudies #ClinicalTrials #ClinicalResearchStudy #ResearchStudy #Temecula #RiversideCounty #VikingClinicalResearch #VikingCR

#HighlyCitedPapers 📝 Functionalized Liposome and Albumin-Based Systems as Carriers for Poorly Water-Soluble Anticancer Drugs: An Updated Review — Teixeira, Carvalho and Castanheira. In this paper, the authors focused on the recent developments of functionalized #nanosystems used to carry poorly water-soluble drugs, with special emphasis on #liposomes and albumin-based nanosystems, two major classes of organic #nanocarriers with formulations already approved by the U.S. Full text is available 👇 https://lnkd.in/dAig3knj #medicine #health #research #science

Diffuse Cutaneous Systemic Sclerosis (DcSSc) Drugs Market Size Share 2023 https://lnkd.in/eEjw5VWP #marketanalysis #marketresearch #marketresearchreports #businessintelligence

#Nefopam_Hydrochloride Market Estimated to Expand at a Robust CAGR over 2023–2032 https://lnkd.in/gPPynrSN Lifestyle changes, lack of physical activity, and the increased number of surgical operations contribute to increased pain and related ailments worldwide, simultaneously increasing the #demand for painkilling drugs. The increased #demand is likely to promote the #growth of the #nefopam market. Non-opioids painkillers are being used as a substitute for opioid painkillers due to the opioid crisis and a reduction in opioid painkiller prescriptions. Biosynth TargetMol Merck Group CARBONE SCIENTIFIC CO., LTD 3B Scientific TCI Group (Transport Corporation of India Limited) MedChemExpress LLC Vesinov Co., Ltd ACHEM BOC Sciences J&K Scientific Ltd.

The transformative potential of the new weight-loss drugs - twenty-two empirical predictions: these have the potential to be personally, socially, and economically transformative. https://lnkd.in/e8RhGUNq #semaglutide #ozempic #NovoNordisk #EliLilly #healthyeating #predictions #obesitymedicine #burnbabyburn #MetabolismBoost

🌍💊 The Future of Osteoporosis Treatment: A Global Perspective 🌍💊 Osteoporosis, a condition affecting over 200 million individuals worldwide, is seeing a surge in drug advancements and market growth. With the global osteoporosis drugs market projected to reach a staggering US$ 17.52 Billion by 2030, there's a lot to unpack! 🔍 Key Insights: Osteoporosis Overview: This ailment weakens bones, making them prone to fractures. Alarmingly, 1 in 3 women and 1 in 5 men globally are at risk of osteoporotic fractures. Treatment Landscape: Despite the availability of several authorized drugs, treatment rates remain low. The introduction of new drugs like bisphosphonates and teriparatide has enhanced treatment safety and effectiveness. Branded vs. Generic: With patent expirations on branded drugs, generic versions are gaining traction due to their cost-effectiveness and government policies promoting their use. RANKL Inhibitors: These are projected to have a significant market share in the global osteoporosis market, offering effective fracture risk reduction. Oral vs. Injectable: While oral drugs like alendronate (Fosamax) are preferred for their convenience, injectables like denosumab (Prolia) provide immediate effects. With extensive R&D efforts, the osteoporosis drug market is evolving rapidly, offering hope for improved treatments and better patient outcomes. Stay informed about the latest trends in osteoporosis treatment! 🦴🌟 #HealthcareNews #Centerinsuranceandfinancialservices #CIFS #Medicare #Lifeinsurance #Healthinsurance #NMO #Aetna #Cigna #Humana #UHC #Devoted #Anthem #Wellcare #Joinus #Teamwork #Sales #Networking #Smallbusiness #Life #Healthylifestyle

Muscle Relaxant Drugs Market Expected to Hit a Valuation of US$ 5.4 Billion During 2024-2032, CAGR of 3.8% | IMARC Group The global muscle relaxant drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032. Request a Sample Report: https://lnkd.in/d8v5aUhx The escalating number of sports injuries and accidents across the globe, the growing popularity of combination therapies that involve the simultaneous use of drugs, and the rising road traffic accidents are some of the major factors propelling the market. Want to Know More about the Market - Explore Full Report: https://lnkd.in/ddHaTmWz #MuscleRelaxantDrugsMarket #MuscleRelaxantDrugs #MuscleRelaxantDrugsCompanies #IMARCGroup #MarketResearchReport #MarketReport #IndustryReport #USA #Marketing #Business #MarketResearch #MarketStrategy

Muscle Relaxant Drugs Market Expected to Hit a Valuation of US$ 5.4 Billion During 2024-2032, CAGR of 3.8% | IMARC Group The global muscle relaxant drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2032, exhibiting a growth rate (CAGR) of 3.8% during 2024-2032. Request a Sample Report: https://lnkd.in/d8v5aUhx The escalating number of sports injuries and accidents across the globe, the growing popularity of combination therapies that involve the simultaneous use of drugs, and the rising road traffic accidents are some of the major factors propelling the market. Want to Know More about the Market - Explore Full Report: https://lnkd.in/ddHaTmWz #MuscleRelaxantDrugsMarket #MuscleRelaxantDrugs #MuscleRelaxantDrugsCompanies #IMARCGroup #MarketResearchReport #MarketReport #IndustryReport #USA #Marketing #Business #MarketResearch #MarketStrategy

Have you ever had so much product-market fit that you've destabilised your country's economy? The recent success of Danish drugmaker, Novo Nordisk (NVO) is wild. Sales of Novo Nordisk's anti-obesity drugs, Ozempic and Wegovy are through the roof, especially in the USA where an estimated 100 million people are obese. "Analysts estimate Novo Nordisk’s weight-loss drug sales to be $6.1 billion this year and to reach nearly $15 billion annually in 2027…" NOVO is moving such a huge amount of dollars into Danish kroner that it is boosting the value of the Krone, which is required to be pegged to the Euro. In response, the central bank of Denmark has had to reduce interest rates. I love this line from a WSJ article - "Lower interest rates also benefit home buyers who can secure mortgage rates somewhat lower than in the rest of Europe..." Someone in Denmark is getting a great 25-year rate on their dream home because of the obesity epidemic in the USA. https://lnkd.in/eK7BfMVq

Muscle Relaxant Drugs Market Predicted to Hit US$ 4.75 Billion by 2028, Growing at a CAGR of 4.20% during 2023-2028 The global muscle relaxant drugs market size reached US$ 3.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.75 Billion by 2028, exhibiting a growth rate (CAGR) of 4.20% during 2023-2028. Request a Sample Report: https://lnkd.in/d8v5aUhx The escalating number of sports injuries and accidents across the globe, the growing popularity of combination therapies that involve the simultaneous use of drugs, and the rising road traffic accidents are some of the major factors propelling the market. Want to Know More about the Market - Explore Full Report: https://lnkd.in/ddHaTmWz #MuscleRelaxantDrugsMarket #MuscleRelaxantDrugs #MuscleRelaxantDrugsCompanies #IMARCGroup #MarketResearchReport #MarketReport #IndustryReport #USA #Marketing #Business #MarketResearch #MarketStrategy